Brad Hirsch, MD, is cofounder of Highlander Health, a firm advancing evidence generation and personalized health care for the new era of medical innovation.  Dr. Hirsch is an oncologist, trialist, entrepreneur, and product leader dedicated to driving transformation at the intersection of research and care. With a deep expertise in value-based care, Dr. Hirsch has dedicated his career to advancing clinical trials and integrating groundbreaking research into everyday clinical practice. Highlander Health has two parts. Highlander Health Institute is an all-stakeholder platform that creates transparent answers to how best to assure safe, effective, and accessible treatments. Highlander Health Partners invests in companies and technology crucial to personalized care for all. The first acquisition of Target RWE was announced in January 2025. Prior to Highlander Health, Dr. Hirsch served as Head of Product at Verily, Alphabet's life sciences company where he led the development and delivery of solutions to accelerate clinical research and improve care. He joined Verily through its acquisition of SignalPath, a clinical trials technology solution, where he was cofounder, CEO, and Chair. Research sites and sponsors use SignalPath to run more efficient and effective clinical research studies, and under Dr. Hirsch's leadership, it was widely adopted by leading health systems and sponsors. Previously, Brad held roles at Flatiron Health, Texas Oncology, and US Oncology, and he served on the faculty of Duke University.